Clinical Trial

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This research study is investigating whether alpha beta T-cell depleted hematopoietic stem cell transplant (HSCT) can be an immune system replacement for Crohn disease patients and whether this is safe and effective for patients with early onset, medically refractory Crohn disease.
Trial Details
NCT Number NCT06986382
Lead Sponsor Stanford University
Conditions Crohn Disease
Enrollment 14 participants
Start Date 2025-07
Primary Completion 2037-07 (estimated)
Study Completion 2040-07 (estimated)
Updated on ClinicalTrials.gov 2025-05-23